The Trump administration will end a subsidy program, meant to keep premiums stable for Medicare prescription drug plans, after 2026, the Centers for Medicare & Medicaid Services said on Tuesday.
The agency said its review of 2027 bids showed insurers have gained enough experience with Medicare Part D to accurately price their plans without support from the program.
